Cibus stock analysis
Want to see CBUS full AI Analyst Report?
Cibus (CBUS) Stock Price & Analysis
CBUS Stock Chart & Stats
- Day’s Range
- $1.02 - $1.14
- 52-Week Range
- $1.02 - $4.19
- Previous Close
- $1.09
- Volume
- N/A
- Average Volume (3M)
- 91.75K
- Market Cap
- $86.36M
- Enterprise Value
- $408.34M
- Total Cash (Recent Filing)
- $10.71M
- Total Debt (Recent Filing)
- $31.89M
- Price to Earnings (P/E)
- ―
- Beta
- 2.50
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- -0.19
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Gene-editing Platform
Cibus’s Direct Breeding platform offers a potentially durable advantage through faster trait development, multi-edit capability, and compatibility with customers’ elite germplasm. Its non-competing model may also make the technology easier for seed companies of different sizes to adopt.
Commercial Pipeline Progress
Positive field performance and movement into customer testing indicate that Cibus is progressing beyond laboratory development toward commercial validation. Advancement across rice, biofragrance, and partner-funded programs broadens potential future revenue sources and supports platform credibility.
Improving Revenue And Gross Profit
Revenue growth and the shift to positive gross profitability show improving monetization of Cibus’s collaboration and trait-development activities. Although the base remains small, sustained execution could improve operating leverage as partner programs and commercial products advance.
Bears Say
Limited Cash Runway
The short cash runway creates a durable financing constraint while Cibus continues funding development and commercialization. A near-term capital raise could reduce financial flexibility and may compete with pipeline investment, particularly before major royalty or product revenue begins.
Persistent Cash Burn
Substantial ongoing cash consumption means Cibus has not yet reached a self-funding operating model. Continued investment in the pipeline will therefore depend on financing, partners, or future commercialization proceeds, increasing exposure to execution and funding timing.
Regulatory And Revenue Timing
Dependence on future regulatory rules and downstream customer decisions can delay commercialization even when technical work progresses. Such timing uncertainty makes revenue conversion less predictable and extends the period during which Cibus must fund operations before recurring monetization develops.
Cibus News
Cibus: Buy Rating Reaffirmed as Cost Discipline and Regulatory Tailwinds Support Growth; $25 Price Target Maintained
Amit Dayal, an analyst from H.C. Wainwright, maintained the Buy rating on Cibus. The associated price target remains the same with $25.00. Amit Dayal has given his Buy rating due
Cibus transfers gene-edited materials for herbicide tolerance in rice to Interoc
Cibus (CBUS) announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and production in anticipation
CBUS FAQ
What was Cibus’s price range in the past 12 months?
What is Cibus’s market cap?
When is Cibus’s upcoming earnings report date?
How were Cibus’s earnings last quarter?
Is Cibus overvalued?
Does Cibus pay dividends?
What is Cibus’s EPS estimate?
How many shares outstanding does Cibus have?
What happened to Cibus’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cibus?
What is the TipRanks Smart Score and how is it calculated?
Cibus Stock Smart Score
Company Description
Cibus
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Craig Wichner
- Employees
- 118
- Website
- www.cibus.com
- Address
- 6455 Nancy Ridge Drive, San Diego, CA, 92121, US
Cibus (CBUS) Earnings & Revenues
CBUS Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, with management highlighting strong execution across biofragrances, rice, partner-funded crop programs, Direct Breeding technology, regulatory progress and cost reductions. Revenue increased 35% for the first nine months, losses and operating expenses improved, and several programs advanced toward commercialization. The principal negatives were the $10.7 million cash balance, expected need for near-term additional capital, approximately $35 million annualized net cash usage, continuing net losses and uncertainty around certain regulatory timelines. Highlights significantly outweighed the lowlights.
View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |











